Back to Cancer Australia's website

Cancer Australia

Select a guideline

Recommendations for Aromatase inhibitors as adjuvant endocrine therapy

Strengths and weaknesses of the evidence

The randomised trials discussed in this report are large, well designed, and well conducted. The short-term effects of aromatase inhibitors on disease-free survival in post-menopausal women with hormone receptor-positive early breast cancer are strong and consistent across a range of populations, agents and settings. Information about long-term effects on overall survival and adverse events is not yet available, and even with longer follow-up will be limited by unblinding and crossover in some trials. Clinical practice recommendations developed by the NBOCC* will be reviewed as additional significant evidence becomes available and revised as required.

Published using CeCC Docbook Manager